IgAN

Advertisement
Charlotte RobinsonIgA Nephropathy | November 20, 2024
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
Read More
Jonathan Barratt, PhDASN Kidney Week 2024 | November 15, 2024
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
Victoria SochaASN Kidney Week 2024 | November 6, 2024
A novel endothelin receptor type A selective antagonist showed a meaningful reduction in proteinuria in patients with IgAN.
Victoria SochaASN Kidney Week 2024 | November 7, 2024
Treatment of IgA nephropathy with felzartamab led to sustained proteinuria reduction and reduced eGFR decline.
Jonathan Barratt, PhDASN Kidney Week 2024 | November 8, 2024
Jonathan Barratt discussed his research on the anti-APRIL antibody sibeprenlimab in the treatment of IgA nephropathy.
Victoria SochaASN Kidney Week 2024 | November 7, 2024
BAFF and APRIL inhibitor atacicept reduced UPCR, hematuria, and Gd-IgA1 and stabilized eGFR in patients with IgAN.
Charlotte RobinsonASN Kidney Week 2024 | October 30, 2024
IgAN was a hot topic at ASN Kidney Week and was the focus of an exhibitor spotlight on pathogenesis and the role of APRIL.
Charlotte RobinsonIgA Nephropathy | November 20, 2024
Could the systemic inflammatory response index (SIRI) be a useful measure of renal prognosis in IgA nephropathy (IgAN)?
Charlotte RobinsonIgA Nephropathy | November 20, 2024
Diffuse magnetic imaging resonance shows promise for evaluating clinical and pathological changes in patients with IgAN.
Charlotte RobinsonASN Kidney Week 2024 | October 22, 2024
Surveyed physicians indicated that IgAN patients were referred to them late and not all potential cases had a timely biopsy.
Charlotte RobinsonASN Kidney Week 2024 | October 22, 2024
C3 plays a key role in the formation of Gd-IgA1-containing IC with a nephritogenic capacity for IgAN.
Charlotte RobinsonASN Kidney Week 2024 | October 22, 2024
Clinical improvement does not always reflect pathology, so renal biopsy may be needed to determine IgAN treatment efficacy.
Charlotte RobinsonASN Kidney Week 2024 | October 22, 2024
Even when levels are below the current KDIGO threshold, proteinuria in IgAN indicates a risk of kidney failure.
Charlotte RobinsonASN Kidney Week 2024 | October 30, 2024
Researchers found evidence that anti-mesangium IgA is involved in the pathogenesis of human IgAN.
Victoria SochaASN Kidney Week 2024 | October 31, 2024
Data from patient charts and surveys of nephrologists shed light on the future of individualizing treatment for IgAN.
Charlotte RobinsonASN Kidney Week 2024 | November 6, 2024
A biopsy registry linked with administrative databases proved to be a practical way of studying IgAN at the population level.
Charlotte RobinsonASN Kidney Week 2024 | October 22, 2024
Researchers identified six candidate loci that were significantly associated with IgA nephropathy prognosis.
Charlotte RobinsonASN Kidney Week 2024 | October 22, 2024
The largest SnRNA-Seq profiling of IgAN kidney cells to date identified noteworthy cell-specific pathways in IgA nephropathy.
Charlotte RobinsonASN Kidney Week 2024 | November 18, 2024
A study examined the impact loin pain has on IgAN patients' quality of life and strategies to manage the pain.
Charlotte RobinsonASN Kidney Week 2024 | October 22, 2024
Analysis of single-nucleus data described heterogeneity in IgAN and found pathogenic alterations in the IgAN transcriptome.
Advertisement
Advertisement
Advertisement
Latest News

November 20, 2024